RedHill Biopharma Files 6-K, Incorporates Prior Filings
Ticker: RDHL · Form: 6-K · Filed: Oct 20, 2025 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Oct 20, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $4 m, $2 million, $4 Million |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, registration, administrative
Related Tickers: RHBP
TL;DR
RHBP files 6-K, referencing old S-8 filings. No new material info.
AI Summary
RedHill Biopharma Ltd. filed a Form 6-K on October 20, 2025, to report its status as a foreign private issuer. This filing incorporates by reference previous registration statements on Form S-8, including one from October 29, 2015, related to its equity incentive plans.
Why It Matters
This filing serves as an update for investors regarding the company's ongoing reporting obligations and its history of equity incentive plans.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information.
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Filer of the 6-K
- October 20, 2025 (date) — Filing date of the 6-K
- Form 6-K (document) — Type of SEC filing
- Form S-8 (document) — Incorporated registration statement
- October 29, 2015 (date) — Date of an incorporated S-8 filing
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K is to report RedHill Biopharma Ltd.'s status as a foreign private issuer and to incorporate by reference previous registration statements.
What type of registration statements are being incorporated by reference?
Registration statements on Form S-8 are being incorporated by reference.
When was one of the referenced Form S-8 registration statements filed?
One of the referenced Form S-8 registration statements was filed on October 29, 2015.
Is this filing expected to contain new financial information?
No, this filing is a routine administrative report and is not expected to contain new financial information, as it primarily incorporates previous filings.
What is RedHill Biopharma Ltd.'s principal executive office address?
RedHill Biopharma Ltd.'s principal executive offices are located at 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel.
Filing Stats: 694 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2025-10-20 09:04:43
Key Financial Figures
- $4 m — r the agreement, Cumberland will invest $4 million, payable in two equal tranches -
- $2 million — illion, payable in two equal tranches - $2 million at closing and $2 million within 12 mon
- $4 Million — 5, entitled: "RedHill's Talicia Secures $4 Million Strategic Investment and U.S. Co-Commer
Filing Documents
- zk2533864.htm (6-K) — 15KB
- exhibit_99-1.htm (EX-99.1) — 39KB
- image00001.jpg (GRAPHIC) — 308KB
- 0001178913-25-003524.txt ( ) — 480KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: October 20, 2025 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer